Conditions: Turner Syndrome Renal Insufficiency, Chronic Pituitary Diseases Dwarfism
Keywords: growth child development growth hormone inadequate growth hormone secretion growth failure
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 251
Healthy volunteers: no

Brief summary:
The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.

Detailed description:

Arms:
arm 1: Patients received daily subcutaneous (s.c.) injections of NutropinAq 10 milligrams (mg)/2 milliliters (mL) for 6 months. The therapeutic daily doses administered were as follows:

* GHD patients: 0.025 - 0.035 mg/ kilogram (kg) bodyweight
* TS patients: up to 0.05 mg/kg bodyweight
* CRI patients: up to 0.05 mg/kg bodyweight

Patients visited the study clinic for a baseline visit and for 2 other visits every 3 months (Weeks 12 and 24). Additional home assessments were made at Weeks 21, 22 and 23.

The investigator determined the dose administered to each patient, and it was recommended to perform the injection in the evening.

Interventions: intervention 1: Somatropin (rDNA origin)
Intervention descriptions: intervention 1: Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.

Protocol document: